Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC

NCT01848613 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: Vinorelbine

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS